{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134765","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.302135+00:00","generated_at":"2026-05-29T05:07:04.195677+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sutro selects luvelta dose for registrational ovarian cancer trial; 32% ORR in Part 1","bullets":["Selected dose: 5.2 mg/kg with prophylactic pegfilgrastim for 2 cycles then 4.3 mg/kg for subsequent cycles.","Topline Part 1 (5.2 mg/kg, N=25): ORR 32%, DCR 96%; half of patients ineligible for approved FRα-targeting ADC.","88% of patients received prior bevacizumab; Grade 3+ neutropenia 32%, no febrile neutropenia.","Part 2 registrational trial to enroll ~500 patients randomized 1:1 luvelta vs investigator's choice chemo."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134765","json":"https://secwatch.observer/filing/0000950170-24-134765.json","markdown":"https://secwatch.observer/filing/0000950170-24-134765.md","text":"https://secwatch.observer/filing/0000950170-24-134765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024134765/0000950170-24-134765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024134765/stro-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:07:04.195677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}